Which of the following is the most common type of enzyme inhibition encountered in metabolic pathways and drug interactions?

Explanation

## Most Common Enzyme Inhibition Type **Key Point:** Competitive inhibition is the most frequently observed and clinically relevant form of enzyme inhibition in both normal metabolism and pharmacotherapy. ### Why Competitive Inhibition Predominates 1. **Structural basis**: Competitive inhibitors structurally resemble the natural substrate and bind to the active site with high affinity, competing directly for enzyme-substrate complex formation. 2. **Reversibility**: Most competitive inhibitions are reversible, allowing physiological regulation and drug efficacy modulation. 3. **Prevalence in drug design**: The majority of clinically used drugs work via competitive inhibition—they are substrate analogues that bind the active site. ### Comparison of Inhibition Types | Feature | Competitive | Non-competitive | Uncompetitive | Allosteric | |---------|---|---|---|---| | **Binding site** | Active site | Allosteric site | Enzyme-substrate complex | Regulatory site | | **Reversibility** | Usually reversible | Reversible or irreversible | Reversible | Reversible | | **Frequency in nature** | Most common | Moderate | Rare | Regulatory role | | **Km change** | Increased | Unchanged | Decreased | Variable | | **Vmax change** | Unchanged | Decreased | Decreased | Decreased | | **Substrate concentration override** | Yes (high [S] overcomes) | No | No | Depends on allosteric effect | ### Clinical Examples of Competitive Inhibition - **Statins** vs HMG-CoA reductase (cholesterol synthesis) - **ACE inhibitors** vs angiotensin-converting enzyme - **Methotrexate** vs dihydrofolate reductase (substrate analogue) - **Cimetidine** vs cytochrome P450 enzymes - **Allopurinol** vs xanthine oxidase **High-Yield:** Competitive inhibition is the **only type** that can be overcome by increasing substrate concentration—a key distinguishing feature tested in NEET PG. **Clinical Pearl:** Drug-drug interactions via competitive inhibition are common and clinically significant; understanding this mechanism is essential for predicting pharmacokinetic interactions. ### Kinetic Signature $$V_{max} \text{ remains unchanged; } K_m \text{ increases by factor } (1 + \frac{[I]}{K_i})$$ This means the enzyme is still capable of the same maximum velocity, but requires a higher substrate concentration to achieve it.